According to study conducted by Shimizu et al., GSK-3β is essential for the development of acquired resistance to lorlatinib in ALK-positive NSCLC, which is mediated by lorlatinib intermediate-resistant cells. This evidence concerns the gene GSK3B and non-small cell lung carcinoma.